Basic Stats
| CIK | 1503274 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Quanterix Corporation
SEC Filings (Chronological Order)
This page provides a complete, chronological list of SEC Filings, excluding ownership filings which we provide elsewhere.
| August 25, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| August 8, 2025 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| August 7, 2025 |
Amendment to Supply and Manufacturing Agreement Exhibit 10.5 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH INFORMATION HAS BEEN OMITTED BECAUSE (i) IT IS NOT MATERIAL, AND (ii) IT WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED. THIRD AMENDMENT TO SUPPLY and MANUFACTURING AGREEMENT This Amendment (the “3rd Amendment”) is made and entered into effective as of January 1, 2025 (the |
|
| August 7, 2025 |
Exhibit 3.1 QUANTERIX CORPORATION RESTATED BYLAWS (effective August 5, 2025) ARTICLE I - STOCKHOLDERS Section 1. Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Di |
|
| August 7, 2025 |
q225earningsslides 1 Roadmap to Cash Flow Breakeven in 2026 Q3 2025 Q4 2025 Q1 2026 $64M of the total $85M Cost reduction already implemented Major Milestones Cost Reduction Implemented (Annualized) ✓ Implement one commercial team ✓ Eliminate duplicate G&A • Complete physical consolidation • Implement one Manufacturing team • Combine Lab Services • Complete all Systems and Financial integration $67M $85M $29M Q2 2025 $64M Cost Reduction Realized (in the quarter) $3M $12M ✓ Pre-close cost actions in commercial and operations $15M $21M 2 2025 2026 ~$120M Cash1 $163M cash1 at close (July ‘25) >$100 million cash1 on hand by the time we turn cash flow positive >$100M Cash flow positive in 2026 1. |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 7, 2025 |
Quanterix Releases Financial Results for the Second Quarter of 2025 Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2025 BILLERICA, Mass. – August 7, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2025. “Through our combination with Akoya Biosciences, we have created a high-margin, hig |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 4, 2025 |
Exhibit 10.1 Execution Version COOPERATION AGREEMENT This cooperation agreement (this “Agreement”) is made and entered into as of August 4, 2025, by and between Quanterix Corporation, a Delaware corporation (the “Company”), on the one hand, and Kent Lake PR LLC, a Puerto Rico limited liability company and the general partner of Kent Lake Partners LP, a Delaware limited partnership (together, “Kent |
|
| August 4, 2025 |
Exhibit 99.1 Quanterix Announces Cooperation Agreement with Kent Lake Capital Company and Kent Lake Capital Agree to Identify New Independent Board Member Company will Seek Shareholder Approval to De-Classify its Board of Directors Board of Directors to Adopt Majority Voting Standard in Uncontested Director Elections BILLERICA, Mass.-(BUSINESS WIRE)-Aug. 4, 2025- Quanterix Corporation (“Quanterix” |
|
| July 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 18, 2025 |
Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| July 11, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities (1) Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee (2) Equity Common Stock, par value $0. |
|
| July 11, 2025 |
Form of Inducement Award Grant Notice and Inducement Award Grant Agreement (RSUs). Exhibit 4.2 Restricted Stock Unit No. QUANTERIX CORPORATION Inducement Award Grant Notice 1. Name and Address of Recipient: (“Recipient”) 2. Date of Grant (“Grant Date”) of Restricted Stock Unit Award: 3. Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This award of restricted stock units (“Restricted Stock Unit Award”) shall vest in full on the first annivers |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 11, 2025 |
As filed with the Securities and Exchange Commission on July 11, 2025 As filed with the Securities and Exchange Commission on July 11, 2025 Registration No. |
|
| July 8, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix Completes Acquisition of Akoya Biosciences, Creating the First Integrated Platform Capable of Measuring Biomarkers Across the Blood and Tissue Continuum BILLERICA, Mass. – July 8, 2025 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced |
|
| July 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| July 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| June 16, 2025 |
PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration No. 333-284932 PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT Dear Stockholders of Akoya Biosciences, Inc.: As previously announced, Quanterix Corporation (“Quanterix”), Akoya Biosciences, Inc. (“Akoya”) and Wellfleet Merger Sub, Inc., a wholly owned subsidiary of Quanterix (“Merger Sub”), entered into an Amended and Restated Agreeme |
|
| June 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted |
|
| June 11, 2025 |
Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Via EDGAR June 11, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| June 4, 2025 |
As filed with the Securities and Exchange Commission on June 3, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on June 3, 2025 No. |
|
| June 4, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated April 27, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The Me |
|
| June 3, 2025 |
Via EDGAR June 3, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington D.C. 20549 Attention: Margaret Sawicki and Lauren Nguyen Re: Quanterix Corporation Post-Effective Amendment No. 1 to Registration Statement on Form S-4 Filed May 21, 2025 File No. 333-284932 Dear Mses. Sawicki and Nguyen: On beh |
|
| June 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Quanterix Corporation (Exact name of registrant as specified in its charter) Delaware 001-38319 (State or other jurisdiction of incorporation) (Commission file number) 900 Middlesex Turnpike, Billerica, MA 01821 (Address of principal executive offices, zip code) Vandana Sriram Chief Financ |
|
| May 23, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted |
|
| May 21, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carryforward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0. |
|
| May 21, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated April 27, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, and “Th |
|
| May 21, 2025 |
Form of Proxy Card for Special Meeting of Akoya Biosciences, Inc. Exhibit 99.3 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V69045-S12593 1. To adopt the Merger Agreement, which is further described in the section titled "The Merger Agreement" of the proxy |
|
| May 21, 2025 |
As filed with the Securities and Exchange Commission on May 20, 2025 Table of Contents As filed with the Securities and Exchange Commission on May 20, 2025 No. |
|
| May 14, 2025 |
Exhibit 16.1 May 14, 2025 Securities and Exchange Commission 100 F Street, N.E. Washington, DC 20549 Commissioners: We have read Item 4.01 of Form 8-K dated May 9, 2025, of Quanterix Corporation and are in agreement with the statements contained in the first sentence of the first paragraph and the second, third, fourth, fifth, sixth, seventh, eighth and ninth paragraphs under (a) Dismissal of Prev |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2025 |
Quanterix Releases Financial Results for the First Quarter of 2025 Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2025 BILLERICA, Mass. – May 12, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 12, 2025 |
Quanterix Releases Financial Results for the First Quarter of 2025 Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2025 BILLERICA, Mass. – May 12, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2025. "During a time when market resource constraints threaten to slow scientific progress, |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| April 30, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 29, 2025 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT, dated as of April 28, 2025 (this “Amendment”), is made by and between (i) Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and (ii) Quanterix Corporation, a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to herein individually as a “Party, |
|
| April 29, 2025 |
Exhibit 10.3 Execution Version VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of April 28, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”), and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, |
|
| April 29, 2025 |
EXHIBIT 10.2 AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT THIS AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT, dated as of April 28, 2025 (this “Amendment”), is made by and between (i) Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and (ii) Quanterix Corporation, a Delaware corporation (“Purchaser”). The Company and Purchaser are referred to herein individually as a “Party, |
|
| April 29, 2025 |
Exhibit 10.3 Execution Version VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of April 28, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”), and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, |
|
| April 29, 2025 |
Exhibit 99.2 Amended Merger Agreement Synergistic Combination Delivering Compelling Strategic and Financial Benefits and Long - Term Value for Stockholders April 2025 Legal Information 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya” or “AKYA”) by Quanterix Corporation (“Quanterix” or “QTRX”), Quanterix will file with the Securities |
|
| April 29, 2025 |
EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of April 28, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 16 ARTICLE 2 THE MERGER 17 2.01 Shares of Merger Sub 17 2.02 The Merger 17 2.03 Closing 17 2.04 Effective Time 18 2.05 Effect |
|
| April 29, 2025 |
Exhibit 99.2 Amended Merger Agreement Synergistic Combination Delivering Compelling Strategic and Financial Benefits and Long - Term Value for Stockholders April 2025 Legal Information 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed acquisition of Akoya Biosciences, Inc. (“Akoya” or “AKYA”) by Quanterix Corporation (“Quanterix” or “QTRX”), Quanterix will file with the Securities |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2025 Date of Report (Date of earliest event reported) QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 29, 2025 |
EXHIBIT 10.1 CONSENT AND WAIVER This CONSENT AND WAIVER (this “Consent and Waiver”) is made and entered into as of April 28, 2025, by each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”) and Quanterix Corporation, a Delaware corporation (“Parent”). WHEREAS, Parent, Wellfleet Merger Sub, Inc., a Delaware corporation |
|
| April 29, 2025 |
EXHIBIT 10.1 CONSENT AND WAIVER This CONSENT AND WAIVER (this “Consent and Waiver”) is made and entered into as of April 28, 2025, by each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”) and Quanterix Corporation, a Delaware corporation (“Parent”). WHEREAS, Parent, Wellfleet Merger Sub, Inc., a Delaware corporation |
|
| April 29, 2025 |
, 2025, by and among the Registrant, Wellfleet Merger Sub, Inc., and Akoya Biosciences, Inc. EXHIBIT 2.1 AMENDED AND RESTATED AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of April 28, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 16 ARTICLE 2 THE MERGER 17 2.01 Shares of Merger Sub 17 2.02 The Merger 17 2.03 Closing 17 2.04 Effective Time 18 2.05 Effect |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 April 28, 2025 Date of Report (Date of earliest event reported) QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or Other Jurisdiction of Incorporation) (Commission Fil |
|
| April 29, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix and Akoya Biosciences Announce Amended Merger Agreement Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. and MARLBOROUGH, Mass. – April 29, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (N |
|
| April 29, 2025 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Quanterix and Akoya Biosciences Announce Amended Merger Agreement Quanterix Files Updated Investor Presentation Highlighting Compelling Benefits of Combination BILLERICA, Mass. and MARLBOROUGH, Mass. – April 29, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, and Akoya Biosciences (N |
|
| April 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted |
|
| April 24, 2025 |
Kent Lake Q&A with Investment Community Exhibit 1 Kent Lake Q&A with Investment Community April 24, 2025 Q. How did sell-side analysts interpret the market’s reaction to the merger announcement? A. On the Q4 2024 earnings call (March 17, 2025), CEO Masoud Toloue was specifically asked about the market’s negative reaction to the merger announcement. He blamed Quanterix’s share price decline on an “NIH-pressured environment.”1 In contrast |
|
| April 22, 2025 |
Exhibit 1 |
|
| April 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use of the Commission Only (as permitted |
|
| April 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 21, 2025 |
Exhibit 1 |
|
| April 18, 2025 |
Exhibit 1 |
|
| April 18, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| April 15, 2025 |
PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-284932 PROPOSED MERGER — YOUR VOTE IS VERY IMPORTANT Dear Stockholders of Quanterix Corporation and Stockholders of Akoya Biosciences, Inc.: As previously announced, Quanterix Corporation (“Quanterix”), Akoya Biosciences, Inc. (“Akoya”) and Wellfleet Merger Sub, Inc., a wholly owned subsidiary of Quanterix (“Merger |
|
| April 11, 2025 |
Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Via EDGAR April 11, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 10, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 9, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The M |
|
| April 10, 2025 |
Consent of Goldman Sachs & Co. LLC. Exhibit 99.1 April 10, 2025 Board of Directors Quanterix Corporation 900 Middlesex Turnpike, Building 1 Billerica, MA 01821 Re: Amendment No. 3 to the Registration Statement on Form S-4 of Quanterix Corporation (File No. 333-284932), filed April 10, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated January 9, 2025 (“Opinion Letter”), with resp |
|
| April 10, 2025 |
As filed with the Securities and Exchange Commission on April 10, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 10, 2025 No. |
|
| April 10, 2025 |
Via EDGAR April 10, 2025 U.S. Securities and Exchange Commission Division of Corporation Finance Office of Industrial Applications and Services 100 F Street, N.E. Washington D.C. 20549 Attention: Laura McKenzie, Margaret Sawicki and Lauren Nguyen Re: Quanterix Corporation Amendment No. 2 to Registration Statement on Form S-4 Filed April 4, 2025 File No. 333-284932 Dear Mses. McKenzie, Sawicki and |
|
| April 10, 2025 |
Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Via EDGAR April 10, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| April 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| April 4, 2025 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 4, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], by and between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and Quanterix Corporation (the “Holder”). The Company and the Holder are referred to each as a “Party” and collectively herein as the “Parties.” Capitalized terms used herein and |
|
| April 4, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 9, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The M |
|
| April 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN QUANTERIX CORPORATION AND AKOYA BIOSCIENCES, INC. Dated as of April 2, 2025 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Construction 10 ARTICLE II PURCHASE AND SALE 11 Section 2.1 The Purchase and Sale 11 Section 2.2 Closing 12 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY 13 Section 3.1 Organ |
|
| April 4, 2025 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND BETWEEN QUANTERIX CORPORATION AND AKOYA BIOSCIENCES, INC. Dated as of April 2, 2025 TABLE OF CONTENTS ARTICLE I DEFINITIONS 1 Section 1.1 Definitions 1 Section 1.2 Construction 10 ARTICLE II PURCHASE AND SALE 11 Section 2.1 The Purchase and Sale 11 Section 2.2 Closing 12 ARTICLE III REPRESENTATIONS AND WARRANTIES OF THE COMPANY 13 Section 3.1 Organ |
|
| April 4, 2025 |
Consent of Goldman Sachs & Co. LLC. Exhibit 99.1 April 4, 2025 Board of Directors Quanterix Corporation 900 Middlesex Turnpike, Building 1 Billerica, MA 01821 Re: Amendment No. 2 to the Registration Statement on Form S-4 of Quanterix Corporation (File No. 333-284932), filed April 4, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated January 9, 2025 (“Opinion Letter”), with respec |
|
| April 4, 2025 |
Form of Subordination Agreement Exhibit 10.4 FORM OF SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of this [●] day of [●], 202[●], by and among QUANTERIX CORPORATION, a Delaware corporation (“Subordinated Lender”), AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent for the financial institutions or other entit |
|
| April 4, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| April 4, 2025 |
Exhibit 10.2 THE INDEBTEDNESS EVIDENCED BY THIS NOTE IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT BETWEEN THE HOLDER (AS DEFINED BELOW) AND MIDCAP FINANCIAL TRUST. THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD |
|
| April 4, 2025 |
Form of Subordination Agreement Exhibit 10.4 FORM OF SUBORDINATION AGREEMENT This SUBORDINATION AGREEMENT (this “Agreement”) is entered into as of this [●] day of [●], 202[●], by and among QUANTERIX CORPORATION, a Delaware corporation (“Subordinated Lender”), AKOYA BIOSCIENCES, INC., a Delaware corporation (“Borrower”), and MIDCAP FINANCIAL TRUST, a Delaware statutory trust, as Agent for the financial institutions or other entit |
|
| April 4, 2025 |
Form of Registration Rights Agreement Exhibit 10.3 FORM OF REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of [●], by and between Akoya Biosciences, Inc., a Delaware corporation (the “Company”), and Quanterix Corporation (the “Holder”). The Company and the Holder are referred to each as a “Party” and collectively herein as the “Parties.” Capitalized terms used herein and |
|
| April 4, 2025 |
Form of Proxy Card for Special Meeting of Quanterix Corporation. Exhibit 99.3 PLEASE MARK, SIGN, DATE AND RETURN YOUR PROXY CARD PROMPTLY IN THE POSTAGE-PAID ENVELOPE ENCLOSED. QUANTERIX CORPORATION SPECIAL MEETING OF STOCKHOLDERS , 2025 YOUR VOTE IS IMPORTANT Please take a moment now to vote your shares of Quanterix Corporation common stock for the special meeting of stockholders. YOU CAN VOTE TODAY IN ONE OF THREE WAYS: VOTE VIA INTERNET Have your proxy card |
|
| April 4, 2025 |
Form of Proxy Card for Special Meeting of Akoya Biosciences, Inc. Exhibit 99.4 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V69045-S12593 1. To adopt the Merger Agreement, which is further described in the section titled "The Merger Agreement" of the joint |
|
| April 4, 2025 |
Exhibit 10.2 THE INDEBTEDNESS EVIDENCED BY THIS NOTE IS SUBJECT TO THE TERMS OF A SUBORDINATION AGREEMENT BETWEEN THE HOLDER (AS DEFINED BELOW) AND MIDCAP FINANCIAL TRUST. THIS NOTE, AND THE SECURITIES ISSUABLE UPON CONVERSION OF THIS NOTE, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE APPLICABLE SECURITIES LAWS OF ANY STATE, AND MAY NOT BE PLEDGED, SOLD |
|
| April 4, 2025 |
As filed with the Securities and Exchange Commission on April 4, 2025 TABLE OF CONTENTS As filed with the Securities and Exchange Commission on April 4, 2025 No. |
|
| March 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of The Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidenti |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 Table of Contents As filed with the Securities and Exchange Commission on March 28, 2025 No. |
|
| March 28, 2025 |
Form of Proxy Card for Special Meeting of Quanterix Corporation. Exhibit 99.3 PLEASE MARK, SIGN, DATE AND RETURN YOUR PROXY CARD PROMPTLY IN THE POSTAGE-PAID ENVELOPE ENCLOSED. QUANTERIX CORPORATION SPECIAL MEETING OF STOCKHOLDERS , 2025 YOUR VOTE IS IMPORTANT Please take a moment now to vote your shares of Quanterix Corporation common stock for the special meeting of stockholders. YOU CAN VOTE TODAY IN ONE OF THREE WAYS: VOTE VIA INTERNET Have your proxy card |
|
| March 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 28, 2025 |
Consent of Goldman Sachs & Co. LLC. Exhibit 99.1 March 28, 2025 Board of Directors Quanterix Corporation 900 Middlesex Turnpike, Building 1 Billerica, MA 01821 Re: Amendment No. 1 to the Registration Statement on Form S-4 of Quanterix Corporation (File No. 333-284932), filed March 28, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated January 9, 2025 (“Opinion Letter”), with resp |
|
| March 28, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 9, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The M |
|
| March 28, 2025 |
Form of Proxy Card for Special Meeting of Akoya Biosciences, Inc. Exhibit 99.4 Signature [PLEASE SIGN WITHIN BOX] Date Signature (Joint Owners) Date TO VOTE, MARK BLOCKS BELOW IN BLUE OR BLACK INK AS FOLLOWS: KEEP THIS PORTION FOR YOUR RECORDS DETACH AND RETURN THIS PORTION ONLY THIS PROXY CARD IS VALID ONLY WHEN SIGNED AND DATED. V69045-S12593 1. To adopt the Merger Agreement, which is further described in the section titled "The Merger Agreement" of the joint |
|
| March 28, 2025 |
Quanterix Corporation 900 Middlesex Turnpike Billerica, MA 01821 Via EDGAR March 28, 2025 Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| March 19, 2025 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| March 19, 2025 |
As filed with the Securities and Exchange Commission on March 19, 2025 As filed with the Securities and Exchange Commission on March 19, 2025 Registration No. |
|
| March 18, 2025 |
Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| March 17, 2025 |
Exhibit 99.1 Quanterix Releases Financial Results for the Fourth Quarter of 2024 Delivers seventh consecutive quarter of double-digit revenue growth BILLERICA, Mass. – March 17, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. “During the |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2025 |
Amended and Restated Non-Employee Director Compensation Policy EXHIBIT 10.12 Amended and Restated Quanterix Corporation Non-Employee Director Compensation Policy Effective as of January 1, 2025 I.Overview The Board of Directors (the “Board”) of Quanterix Corporation (the “Company”) has approved this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) to provide an inducement to attract and retain the services of qualified persons to |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| March 17, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 17, 2025 |
Exhibit 99.1 Quanterix Releases Financial Results for the Fourth Quarter of 2024 Delivers seventh consecutive quarter of double-digit revenue growth BILLERICA, Mass. – March 17, 2025 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the fourth quarter ended December 31, 2024. “During the |
|
| March 17, 2025 |
DFAN14A 1 n4845x5-dfan14a.htm DFAN14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [] Filed by a party other than the Registrant [X] Check the appropriate box: [] Preliminary Proxy Statement [] Confidential, for Use |
|
| March 17, 2025 |
Quanterix Insider Trading Policy EXHIBIT 19.1 QUANTERIX CORPORATION INSIDER TRADING POLICY TABLE OF CONTENTS Page I. The Need for an Insider Trading Policy 3 II. What is Material Non-Public Information? 3 III. The Consequences of Insider Trading 4 IV. Our Policy 5 General Prohibition on Trading. 5 Transactions by Family Members, Others in Your Household and Entities You Control. 5 Other Companies’ Non-public Information. 1 Person |
|
| March 11, 2025 |
Exhibit 1 Urges Quanterix Shareholders to Vote AGAINST the Proposed Merger with Akoya Biosciences KENT LAKE PR LLC THIS IS NOT A SOLICITATION OF AUTHORITY TO VOTE YOUR PROXY. |
|
| March 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 3, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 3, 2025 |
EXHIBIT 99.1 Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition Comments on Director Nominations Received from Kent Lake BILLERICA, Mass. March 3, 2025 - Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☐ Filed by a party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Ru |
|
| March 3, 2025 |
EXHIBIT 99.1 Quanterix Highlights Compelling Benefits of Akoya Biosciences Acquisition Comments on Director Nominations Received from Kent Lake BILLERICA, Mass. March 3, 2025 - Quanterix Corporation (NASDAQ: QTRX) (“Quanterix” or the “Company”), a company fueling scientific discovery through ultra-sensitive biomarker detection, today reiterated the strategic and financial benefits of its proposed |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| February 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| February 14, 2025 |
Consent of Goldman Sachs & Co. LLC. Exhibit 99.1 February 13, 2025 Board of Directors Quanterix Corporation 900 Middlesex Turnpike, Building 1 Billerica, MA 01821 Re: Initially Filed Registration Statement on Form S-4 of Quanterix Corporation, filed February 13, 2025 (the “Registration Statement”) Ladies and Gentlemen: Reference is made to our opinion letter, dated January 9, 2025 (“Opinion Letter”), with respect to the fairness fro |
|
| February 14, 2025 |
Consent of Perella Weinberg Partners LP. Exhibit 99.2 CONSENT OF PERELLA WEINBERG PARTNERS L.P. We hereby consent to the inclusion of our opinion dated January 9, 2025 appearing as Annex F to, and the reference to such opinion letter under the headings “Summary—Opinion of Akoya’s Financial Advisor”, “The Merger—Akoya’s Reasons for the Merger and Recommendation of the Akoya Board”, “The Merger—Opinion of Akoya’s Financial Advisor”, “The M |
|
| February 14, 2025 |
As filed with the Securities and Exchange Commission on February 13, 2025 Table of Contents As filed with the Securities and Exchange Commission on February 13, 2025 No. |
|
| February 14, 2025 |
Subsidiaries of Quanterix Corporation. Exhibit 21.1 SUBSIDIARIES Company Name Jurisdiction of Incorporation Aushon Biosystems, Inc. Delaware Quanterix Security Corporation Massachusetts Quanterix Netherlands B.V. The Netherlands UmanDiagnostics AB Sweden Quanterix Holdings (Hong Kong) Limited Hong Kong Quanterix Bio-tech (Shanghai) Co., Ltd China Emission Inc. Delaware Wellfleet Merger Sub, Inc. Delaware |
|
| February 14, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-4 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carryforward Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee(3) Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Equity Common Stock, par value $0. |
|
| February 13, 2025 |
Transactions in Shares Effected by Kent Lake Partners LP During the Past Sixty Days EX-1 2 exh1.htm TRANSACTIONS IN THE SHARES Exhibit 1 Transactions in Shares Effected by Kent Lake Partners LP During the Past Sixty Days Nature of Transaction Amount of Securities Purchased/(Sold) Price ($) Date of Purchase/Sale Purchase of Common Stock 6,200 $10.4197 12/13/2024 Purchase of Common Stock 18,265 $10.8185 12/16/2024 Purchase of Common Stock 25,535 $11.1635 12/17/2024 Purchase of Comm |
|
| February 13, 2025 |
EX-3 4 exh3.htm JOINT FILING AGREEMENT Exhibit 3 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including additional amendments thereto) with respect to the Common Stock, $0.001 par value per share, of Quanterix Corporat |
|
| February 13, 2025 |
Letter AGAINST the Proposed QTRX-AKYA Merger Exhibit 2 Letter AGAINST the Proposed QTRX-AKYA Merger Dear Fellow Quanterix Shareholders: Kent Lake has been an institutional investor in Quanterix (“QTRX”, “The Company”) since 2022 and has extensive understanding of both QTRX’s transformational clinical Alzheimer’s blood testing opportunity, as well as its highly recurring and double-digit growth research and translational use business. |
|
| February 11, 2025 |
feb112025425filingfinal Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| January 31, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 16, 2025 |
jpmakoyarule425filing Filed by Quanterix Corporation pursuant to Rule 425 under the Securities Act of 1933, as amended, and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934, as amended Subject Company: Akoya Biosciences, Inc. |
|
| January 16, 2025 |
BOARD OF DIRECTORS AND EXECUTIVE OFFICERS OF QUANTERIX SCHEDULE A BOARD OF DIRECTORS AND EXECUTIVE OFFICERS OF QUANTERIX The name, present principal occupation or employment and citizenship of each member of the Board of Directors and each executive officer of Quanterix are as set forth below. |
|
| January 16, 2025 |
SCHEDULE A Directors and Executive Officers of Akoya Biosciences, Inc. Exhibit 99.1 SCHEDULE A Directors and Executive Officers of Akoya Biosciences, Inc. Name Position Brian McKelligon President, Chief Executive Officer and Director Johnny Elk Chief Financial Officer Jennifer Kamocsay General Counsel Pascal Bamford Chief Clinical Officer Niro Ramachandran Chief Business Officer Robert G. Shepler Director, Chairman of the Board Thomas Raffin Director Thomas P. Schnet |
|
| January 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 14, 2025 |
EXHIBIT 99.1 Quanterix Provides Update on Financial Performance Company announced preliminary Q4 2024 revenue of approximately $34.9 million and FY 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth for the full year BILLERICA, Mass. – Jan. 14, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker dete |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 14, 2025 |
EXHIBIT 99.1 Quanterix Provides Update on Financial Performance Company announced preliminary Q4 2024 revenue of approximately $34.9 million and FY 2024 revenue of approximately $137.2 million, representing 12% year-over-year growth for the full year BILLERICA, Mass. – Jan. 14, 2025 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker dete |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| January 10, 2025 |
First Integrated Solution for Ultra- Sensitive Detection of Blood and Tissue Based Protein Biomarkers Uniquely positioned to speed up market development of new diagnostic testing solutions January 10, 2025 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix Corporation (“Quanterix” or “QTRX”) will file with the U. |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.4 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced our plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. This is a logical next step for Q |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.3 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. Together, we’re creating the first pl |
|
| January 10, 2025 |
EXHIBIT 99.1 Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across transla |
|
| January 10, 2025 |
EXHIBIT 10.2 Execution version STOCKHOLDER LOCK-UP AGREEMENT January 9, 2025 Quanterix Corporation 900 Middlesex Turnpike Billerica, MA Attention: Legal Department Email: [email protected] To the addressee set forth above: The undersigned understands that, on the date hereof, Quanterix Corporation, a Delaware corporation (“Parent”), Wellfleet Merger Sub, Inc., a Delaware corporation and a wholly |
|
| January 10, 2025 |
Why is Quanterix acquiring Akoya? EXHIBIT 99.5 1.Why is Quanterix acquiring Akoya? •The acquisition of Akoya is consistent with our GET strategy and part of the natural evolution of our company. •This is a pivotal step forward in the holistic understanding and treatment of disease. By integrating Akoya’s spatial biology capabilities in tissue with our advanced tools for blood detection, we will create the first integrated solution |
|
| January 10, 2025 |
EXHIBIT 2.1 Execution version AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 15 ARTICLE 2 THE MERGER 16 2.01 Shares of Merger Sub 16 2.02 The Merger 16 2.03 Closing 17 2.04 Effective Time 17 2.05 Effects |
|
| January 10, 2025 |
EXHIBIT 10.1 VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”) and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, as of the date he |
|
| January 10, 2025 |
IMPORTANT ADDITIONAL INFORMATION Exhibit 99.6 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “registration statement”), which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix (the “joint proxy statement/prospectus”), and each of Quanterix |
|
| January 10, 2025 |
qtrx202501108kex992 First Integrated Solution for Ultra- Sensitive Detection of Blood and Tissue Based Protein Biomarkers Uniquely positioned to speed up market development of new diagnostic testing solutions January 10, 2025 2 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix Corporation (“Quanterix” or “QTRX”) will file with the U. |
|
| January 10, 2025 |
EXHIBIT 99.2 Team, Diseases like cancer begin in tissue, spread to blood and often end up in other organs such as lung and liver that ultimately take life. To effectively detect and treat disease, we must measure signals as they follow this pathway. Our vision is to bring clinical and anatomical pathology together to solve this problem. Today we announced our plans to acquire Akoya Biosciences. By |
|
| January 10, 2025 |
EXHIBIT 99.1 Quanterix to Acquire Akoya Biosciences, Creating the First Integrated Solution for Ultra-Sensitive Detection of Blood- and Tissue-Based Protein Biomarkers Complementary offerings will accelerate translation of biomarkers from research to the clinic driving new growth Expanded customer relationships and continuum of solution offerings maximize cross-selling opportunities across transla |
|
| January 10, 2025 |
EXHIBIT 99.1 Operator^ Hello, and welcome to today's call to discuss Quanterix's acquisition of Akoya Biosciences. At this time, our participants have been placed in listen-only mode. The call will be open for your questions following the prepared remarks. As a reminder, this conference call is being recorded and the press release and slide presentation regarding the transactions are available at |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.3 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. Together, we’re creating the first pl |
|
| January 10, 2025 |
EXHIBIT 99.1 Operator^ Hello, and welcome to today's call to discuss Quanterix's acquisition of Akoya Biosciences. At this time, our participants have been placed in listen-only mode. The call will be open for your questions following the prepared remarks. As a reminder, this conference call is being recorded and the press release and slide presentation regarding the transactions are available at |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| January 10, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 10, 2025 |
EXHIBIT 2.1 Execution version AGREEMENT AND PLAN OF MERGER by and among QUANTERIX CORPORATION WELLFLEET MERGER SUB, INC. and AKOYA BIOSCIENCES, INC. Dated as of January 9, 2025 TABLE OF CONTENTS ARTICLE 1 DEFINITIONS 2 1.01 Definitions 2 1.02 Other Definitional Provisions 15 ARTICLE 2 THE MERGER 16 2.01 Shares of Merger Sub 16 2.02 The Merger 16 2.03 Closing 17 2.04 Effective Time 17 2.05 Effects |
|
| January 10, 2025 |
EXHIBIT 99.2 Team, Diseases like cancer begin in tissue, spread to blood and often end up in other organs such as lung and liver that ultimately take life. To effectively detect and treat disease, we must measure signals as they follow this pathway. Our vision is to bring clinical and anatomical pathology together to solve this problem. Today we announced our plans to acquire Akoya Biosciences. By |
|
| January 10, 2025 |
EXHIBIT 10.2 Execution version STOCKHOLDER LOCK-UP AGREEMENT January 9, 2025 Quanterix Corporation 900 Middlesex Turnpike Billerica, MA Attention: Legal Department Email: [email protected] To the addressee set forth above: The undersigned understands that, on the date hereof, Quanterix Corporation, a Delaware corporation (“Parent”), Wellfleet Merger Sub, Inc., a Delaware corporation and a wholly |
|
| January 10, 2025 |
IMPORTANT ADDITIONAL INFORMATION Exhibit 99.6 IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction, Quanterix will file with the U.S. Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4 (the “registration statement”), which will contain a joint proxy statement of Quanterix and Akoya and a prospectus of Quanterix (the “joint proxy statement/prospectus”), and each of Quanterix |
|
| January 10, 2025 |
Why is Quanterix acquiring Akoya? EXHIBIT 99.5 1.Why is Quanterix acquiring Akoya? •The acquisition of Akoya is consistent with our GET strategy and part of the natural evolution of our company. •This is a pivotal step forward in the holistic understanding and treatment of disease. By integrating Akoya’s spatial biology capabilities in tissue with our advanced tools for blood detection, we will create the first integrated solution |
|
| January 10, 2025 |
Subject: Important Update: Quanterix to Acquire Akoya EXHIBIT 99.4 Subject: Important Update: Quanterix to Acquire Akoya [INSERT NAME], I am writing to share an exciting update from Quanterix – we have announced our plans to acquire Akoya Biosciences, Inc., a company that shares our mission to revolutionize the way we understand and treat disease. Below please find the press release we issued with additional details. This is a logical next step for Q |
|
| January 10, 2025 |
EXHIBIT 10.1 VOTING AND SUPPORT AGREEMENT THIS VOTING AND SUPPORT AGREEMENT (this “Agreement”) is made and entered into as of January 9, 2025 by and among Quanterix Corporation, a Delaware corporation (“Parent”) and each of the individuals and entities listed on the signature pages hereto (each, a “Stockholder” and, collectively, the “Stockholders”). WHEREAS, each Stockholder is, as of the date he |
|
| January 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 8, 2025 |
Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| December 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| December 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Comm |
|
| December 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q/A (Amendment No. 1) (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Com |
|
| December 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 1) (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| December 17, 2024 |
Exhibit 2.1 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT HAVE BEEN OMITTED AND REPLACED WITH “[***]”. SUCH INFORMATION HAS BEEN OMITTED BECAUSE (i) IT IS NOT MATERIAL, AND (ii) IT WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF DISCLOSED SHARE PURCHASE AGREEMENT BY AND AMONG QUANTERIX CORPORATION, EMISSION INC., THE SHAREHOLDERS OF EMISSION INC. AND THE SHAREHOLDER REPRESENTATIVE Dated as o |
|
| December 17, 2024 |
Quanterix Expands Capabilities with Strategic Acquisition of EMISSION Exhibit 99.1 Quanterix Expands Capabilities with Strategic Acquisition of EMISSION Builds technology capabilities through vertical integration of proprietary bead technology and drives OEM business BILLERICA, Mass. - December 17, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announc |
|
| November 22, 2024 |
Quanterix Announces Receipt of Expected Notice from Nasdaq EX-99.1 2 qtrx-20241122xex991.htm EX-99.1 Exhibit 99.1 Quanterix Announces Receipt of Expected Notice from Nasdaq BILLERICA, Mass.—November 22, 2024 — Quanterix Corporation (NASDAQ: QTRX) today announced that it received a notice (the “Notice”) on November 21, 2024 from The Nasdaq Stock Market LLC (“Nasdaq”) stating that because the Company has not yet filed its Quarterly Report on Form 10-Q for t |
|
| November 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| November 13, 2024 |
QTRX / Quanterix Corporation / Portolan Capital Management, LLC - SC 13G/A Passive Investment SC 13G/A 1 tm2428231d2sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d –1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d–2. (Amendment No. 1)* Quanterix Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 74766Q101 (CUSIP Number) Sept |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING SEC File Number: 001-38319 CUSIP Number: 74766Q101 (Check one): ☐Form 10-K ☐Form 20-F ☐Form 11-K x Form 10-Q ☐Form 10-D ☐Form N-CEN ☐Form N-CSR For Period Ended: September 30, 2024 ☐Transition Report on Form 10-K ☐Transition Report on Form 20-F ☐Transition Report on Form 11-K ☐Transition |
|
| November 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 11, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| November 12, 2024 |
Quanterix Releases Preliminary Financial Results for the Third Quarter of 2024 Sixth Consecutive Quarter of Double-Digit Growth Reaffirms Full Year 2024 Outlook BILLERICA, Mass. |
|
| October 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 2, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| October 3, 2024 |
Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors Exhibit 99.1 Quanterix Welcomes Ivana Magovčević-Liebisch, Ph.D., J.D. to Board of Directors BILLERICA, Mass. - October 2, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced the appointment of Ivana Magovčević-Liebisch, Ph.D., J.D. to its Board of Directors. Dr. Magovčević-Lieb |
|
| August 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| August 21, 2024 |
Jeffrey Elliott Appointed to Quanterix’s Board of Directors Exhibit 99.1 Jeffrey Elliott Appointed to Quanterix’s Board of Directors BILLERICA, Mass. - August 19, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultra-sensitive biomarker detection, today announced that it appointed Jeffrey Elliott to its Board of Directors. Mr. Elliott brings two decades of senior leadership experience |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 8, 2024 |
Quanterix Releases Financial Results for the Second Quarter of 2024 Exhibit 99.1 Quanterix Releases Financial Results for the Second Quarter of 2024 BILLERICA, Mass. – August 8, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultra-sensitive biomarker detection, today announced financial results for the second quarter ended June 30, 2024. “Our research business once again delivered strong performance in the second quarte |
|
| June 27, 2024 |
QTRX / Quanterix Corporation / Portolan Capital Management, LLC - SC 13G Passive Investment SC 13G 1 tm2418374d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d –1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d–2. (Amendment No. )* Quanterix Corporation (Name of Issuer) Common Stock (Title of Class of Securities) 74766Q101 (CUSIP Number) June 17, 2 |
|
| June 7, 2024 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD SPECIALIZED DISCLOSURE REPORT Quanterix Corporation (Exact name of registrant as specified in its charter) Delaware 001-38319 (State or other jurisdiction of incorporation) (Commission file number) 900 Middlesex Turnpike, Billerica, MA 01821 (Address of principal executive offices, zip code) Vandana Sriram Chief Financ |
|
| May 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 21, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 2, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 7, 2024 |
Quanterix Releases Financial Results for the First Quarter of 2024 Exhibit 99.1 Quanterix Releases Financial Results for the First Quarter of 2024 BILLERICA, Mass. – May 7, 2024 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the first quarter ended March 31, 2024. “Building on the foundation our team developed last year, Quanterix is entering a new in |
|
| April 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 15, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| April 12, 2024 |
Exhibit 10.2 Vandana Sriram April 9, 2024 Delivered via Email RE: Amendment to Employment Agreement Dear Vandana: I am pleased to inform you that the compensation committee of the Board of Directors of Quanterix Corporation (the “Company”) has approved the enhancement of certain executive-level severance and change in control benefits applicable to you. Changes to your employment agreement, dated |
|
| April 12, 2024 |
Exhibit 10.1 Masoud Toloue April 9, 2024 Delivered via Email RE: Amendment to Employment Agreement Dear Masoud: I am pleased to inform you that the compensation committee of the Board of Directors of Quanterix Corporation (the “Company”) has approved a modification to the change in control benefits applicable to you. Changes to your amended and restated employment agreement, dated April 25, 2022 ( |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| March 4, 2024 |
As filed with the Securities and Exchange Commission on March 4, 2024 As filed with the Securities and Exchange Commission on March 4, 2024 Registration No. |
|
| March 4, 2024 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| February 29, 2024 |
Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023 Exhibit 99.1 Quanterix Releases Operating Results for Fourth Quarter and Full Year 2023 BILLERICA, Mass. – February 29, 2023 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2023. “The fourth quarter marked the successful completion |
|
| February 29, 2024 |
Amended and Restated Non-Employee Director Compensation Policy Exhibit 10.14 Amended and Restated Quanterix Corporation Non-Employee Director Compensation Policy Effective as of January 1, 2024 I. Overview The Board of Directors (the “Board”) of Quanterix Corporation (the “Company”) has approved this Amended and Restated Non-Employee Director Compensation Policy (the “Policy”) to provide an inducement to attract and retain the services of qualified persons to |
|
| February 29, 2024 |
Policy relating to recovery of erroneously awarded compensation Exhibit 97.1 Quanterix Corporation Compensation Clawback Policy Adopted November 1, 2023 Purpose The Board of Directors (the “Board”) of Quanterix Corporation (the “Corporation”) has adopted this compensation clawback policy (the “Policy”), which provides for the recoupment of incentive-based compensation in the event of an accounting restatement. This Policy is intended to comply with Section 10D |
|
| February 29, 2024 |
Exhibit 10.2.4 Restricted Stock Unit No. QUANTERIX CORPORATION Restricted Stock Unit Award Grant Notice Restricted Stock Unit Award Grant under the Company’s 2017 Employee, Director and Consultant Equity Incentive Plan 1.Name and Address of Participant: 2.Date of Grant of Restricted Stock Unit Award: 3.Maximum Number of Shares underlying Restricted Stock Unit Award: 4. Vesting of Award: This Restr |
|
| February 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| February 29, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 29, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| February 27, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| February 27, 2024 |
Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance Exhibit 99.1 Quanterix Reschedules Q4 and Full Year 2023 Earnings Conference Call; Reaffirms 2023 Guidance BILLERICA, Mass.- February 26, 2024 - Quanterix Corporation (NASDAQ: QTRX) today announced that it has rescheduled the release of its financial results for the fourth quarter and year ended December 31, 2023 and the associated conference call in order to more closely align the release of such |
|
| February 14, 2024 |
EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2024 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). |
|
| February 14, 2024 |
QTRX / Quanterix Corporation / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Quanterix Corporation (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74766Q101 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| February 13, 2024 |
QTRX / Quanterix Corporation / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01770-quanterixcorp.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Quanterix Corp Title of Class of Securities: Common Stock CUSIP Number: 74766Q101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which th |
|
| January 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 24, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 29, 2024 |
QTRX / Quanterix Corporation / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 QTRXSC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) QUANTERIX CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 74766Q101 (CUSIP Number) DECEMBER 31, 2023 (Date of event which requires filing of this statement) Check the appropri |
|
| January 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2024 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 11, 2024 |
Exhibit 99.1 Create the tools enabling discovery and better health O U R M I S S I O N 1 1. Preliminary unaudited full year results for 2023. 2. The Company is guiding full year 2023 GAAP gross margin percentage to be in the high 50’s, and non-GAAP gross margin percentage to be approximately 50%. GAAP gross margin does not include shipping and handling costs, which include freight and other activi |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num |
|
| November 6, 2023 |
Quanterix Releases Operating Results for Third Quarter 2023 Exhibit 99.1 Quanterix Releases Operating Results for Third Quarter 2023 BILLERICA, Mass. – November 6, 2023 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended September 30, 2023. Third Quarter Financial Highlights ● Revenue was $31.3 million, an 18% increase from $2 |
|
| November 6, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| September 29, 2023 |
QTRX / Quanterix Corp / MILLENNIUM MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 QUANTERIX CORPORATION (Name of Issuer) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities) 74766Q101 (CUSIP Number) SEPTEMBER 26, 2023 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to wh |
|
| August 22, 2023 |
William P. Donnelly Appointed to Quanterix’s Board of Directors Exhibit 99.1 William P. Donnelly Appointed to Quanterix’s Board of Directors Billerica, Mass. – August 21, 2023 – Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it appointed William (Bill) P. Donnelly to its Board of Directors. Mr. Donnelly brings many years of senior leaders |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 17, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| August 9, 2023 |
Employment Agreement, dated August 3, 2023, between the Registrant and Vandana Sriram EXHIBIT 10.1 July 31, 2023 Vandana Sriram Delivered via Email Re: Employment Agreement Dear Vandana: Quanterix Corporation (the "Company") is pleased to offer you the full-time, exempt position of Chief Financial Officer, reporting to Masoud Toloue, Chief Executive Officer. Your start date will be August 21, 2023. This role is required to be on-site 5 days a week in our Billerica, MA office. Congr |
|
| August 9, 2023 |
Quanterix Appoints Vandana Sriram as Chief Financial Officer EXHIBIT 99.1 Quanterix Appoints Vandana Sriram as Chief Financial Officer Billerica, Mass. – August 9, 2023 — Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery and breakthrough diagnostics through ultrasensitive biomarker detection, today announced that it has appointed Vandana Sriram, CPA, as Chief Financial Officer (CFO), effective August 21, 2023. Sriram replaces Mich |
|
| August 8, 2023 |
Exhibit 3.2 QUANTERIX CORPORATION RESTATED BYLAWS (effective August 4, 2023) ARTICLE I - STOCKHOLDERS Section 1.Annual Meeting. An annual meeting of the stockholders, for the election of directors to succeed those whose terms expire and for the transaction of such other business as may properly come before the meeting, shall be held at such place, on such date, and at such time as the Board of Dir |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| August 7, 2023 |
Quanterix Releases Operating Results for Second Quarter 2023 Exhibit 99.1 Quanterix Releases Operating Results for Second Quarter 2023 BILLERICA, Mass. – August 7, 2023 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended June 30, 2023. Second Quarter Financial Highlights ● Total revenue was $31.0 million versus prior year secon |
|
| August 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| June 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: |
|
| May 9, 2023 |
Exhibit 99.2 2023 Guidance We have made a modest positive adjustment to our full year 2023 Revenue and Gross Margin % guidance 1 Gross Margin % Expect FY 2023 GAAP gross margin in the high 40s and non-GAAP gross margin in the mid 40s $4.5 2023 Guidance ~$11.0 2022 Actual Revenue ~$94.5 $99.5 - $106.5 $105.5 $104 - $111 (in millions) Pharma Collaboration(s) Core product and services revenue +9% MP |
|
| May 9, 2023 |
Quanterix Releases Operating Results for First Quarter 2023 Exhibit 99.1 Quanterix Releases Operating Results for First Quarter 2023 BILLERICA, Mass.- May 9, 2023 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the three months ended March 31, 2023. “Our corporate transformation initiated in August 2022 to maximize Quanterix’s full potential is |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission File |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| April 14, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rul |
|
| March 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fi |
|
| March 27, 2023 |
Exhibit 10.1 March 27, 2023 Re: Amended and Restated Employment Agreement Dear Mike: This Amended and Restated Employment Agreement (the “Agreement”) is entered into between you and Quanterix Corporation (the “Corporation”), and is effective on March 27, 2023 (the “Effective Date”). This Agreement fully replaces and supersedes the Employment Agreement between you and the Corporation dated June 22, |
|
| March 6, 2023 |
Exhibit 99.1 Quanterix Releases Operating Results for Fourth Quarter and Full Year 2022; Aligned with Expectations Corporate Transformation: BILLERICA, Mass.- March 6, 2023 - Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced financial results for the fourth quarter and twelve months ended December 31, 2022. “Our |
|
| March 6, 2023 |
Exhibit 99.2 1 Quanterix Corporation Supplemental Schedule of Operating Expenses (Unaudited and in thousands) Three Months Ended December 31 2022 2021 Operating expenses: Research and development $ 5,600 $ 7,734 Selling, general and administrative 19,272 28,423 Subtotal $ 24,872 $ 36,157 Other lease costs 669 — Restructuring 329 — Goodwill impairment — — Impairment expense 8,677 — Subtotal $ 9,675 |
|
| March 6, 2023 |
As filed with the Securities and Exchange Commission on March 6, 2023 As filed with the Securities and Exchange Commission on March 6, 2023 Registration No. |
|
| March 6, 2023 |
EXHIBIT 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Quanterix Corporation (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price(2) Fee Rate Amount of Registration Fee Equity Common Stock, par value $0. |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-38 |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission Fil |
|
| February 14, 2023 |
QTRX / Quanterix Corp / MACQUARIE GROUP LTD - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Quanterix Corp (Name of Issuer) Common Shares (Title of Class of Securities) 74766Q101 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| February 14, 2023 |
EX-99.B EXHIBIT B Powers of Attorney for Macquarie Group Limited and Macquarie Bank Limited incorporated by reference to 13G filings made by Macquarie Group Limited and Macquarie Bank Limited on May 25, 2021. Page 12 of 12 |
|
| February 14, 2023 |
QTRX / Quanterix Corp / GILDER GAGNON HOWE & CO LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (RULE 13d - 102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (Amendment No. 4)* Quanterix Corporation (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74766Q101 (CUSIP Number) December 31, 2022 (Date of Ev |
|
| February 14, 2023 |
QTRX / Quanterix Corp / Camber Capital Management LP - PRIMARY DOCUMENT Passive Investment SC 13G/A 1 camberQTRX13Ga2023.htm PRIMARY DOCUMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Quanterix Corporation (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 74766Q101 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this State |
|
| February 14, 2023 |
EX-99.A EXHIBIT A AGREEMENT TO FILE JOINT ACQUISITION STATEMENTS AGREEMENT made this 2nd day of FEBRUARY, 2021 by and between Delaware Funds® by Macquarie listed on Annex A hereto, Macquarie Investment Management Business Trust, Macquarie Management Holdings, Inc, and the Macquarie Parties listed on Annex B hereto (collectively referred to as the “parties”). WHEREAS, the parties hereto may be deem |
|
| February 14, 2023 |
EX-1 2 camberQTRX-13Ga2023ex1.htm JOINT FILING AGREEMENT EXHIBIT 1 JOINT FILING AGREEMENT This Joint Filing Agreement dated February 14, 2023 is by and between Camber Capital Management LP, a Delaware limited partnership, and Stephen DuBois, an individual (the foregoing are collectively referred to herein as the "Filers"). Each of the Filers may be required to file with the United States Securitie |
|
| February 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
|
| January 9, 2023 |
Quanterix Announces Appointment of Brian Blaser to Board of Directors EX-99.1 2 tm232358d1ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Quanterix Announces Appointment of Brian Blaser to Board of Directors Billerica, Mass. – Jan. 9, 2023 — Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced that it has appointed Brian Blaser to its Board of Directors effective as of January 6, 2023. Mr. Blas |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2023 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission F |
|
| November 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 8, 2022 |
Quanterix Corporation Releases Operating Results for Third Quarter 2022 Exhibit 99.1 Quanterix Corporation Releases Operating Results for Third Quarter 2022 Billerica, Mass. ? November 8, 2022 ? Quanterix Corporation (NASDAQ: QTRX), a company driving scientific discovery through ultrasensitive biomarker detection, today announced operating results for the three months ended September 30, 2022. Financial Highlights ? Revenue of $26.6M for Q3 2022 was flat versus Q3 202 |
|
| November 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 001-38319 20-8957988 (State or other jurisdiction of incorporation) (Commission |
